KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Basic) (2017 - 2025)

Aquestive Therapeutics has reported EPS (Basic) over the past 9 years, most recently at -$0.27 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.27 for Q4 2025, down 42.11% from a year ago — trailing twelve months through Dec 2025 was -$0.79 (down 51.92% YoY), and the annual figure for FY2025 was -$0.78, down 52.94%.
  • EPS (Basic) for Q4 2025 was -$0.27 at Aquestive Therapeutics, down from -$0.14 in the prior quarter.
  • Over the last five years, EPS (Basic) for AQST hit a ceiling of $0.15 in Q1 2023 and a floor of -$0.73 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$0.21 (2022), compared with a mean of -$0.22.
  • Biggest five-year swings in EPS (Basic): crashed 371.43% in 2021 and later skyrocketed 146.88% in 2023.
  • Aquestive Therapeutics' EPS (Basic) stood at -$0.73 in 2021, then surged by 69.86% to -$0.22 in 2022, then surged by 40.91% to -$0.13 in 2023, then tumbled by 46.15% to -$0.19 in 2024, then plummeted by 42.11% to -$0.27 in 2025.
  • The last three reported values for EPS (Basic) were -$0.27 (Q4 2025), -$0.14 (Q3 2025), and -$0.14 (Q2 2025) per Business Quant data.